Seth Harmon
Financieel Directeur/CFO bij VIRIDIAN THERAPEUTICS, INC.
Vermogen: 11 950 $ op 31-05-2024
Profiel
Seth Harmon is currently the Chief Financial & Accounting Officer at Viridian Therapeutics, Inc. He previously worked as the Vice President-Finance at BioNTech US, Inc. from 2017 to 2020.
He also served as the Chief Financial Officer at BioNTech SE.
Mr. Harmon completed his undergraduate degree at Bowdoin College and holds a graduate degree in MBA from Northeastern University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2024 | 1 000 ( 0.00% ) | 11 950 $ | 31-05-2024 |
Actieve functies van Seth Harmon
| Bedrijven | Functie | Begin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Financieel Directeur/CFO | 12-09-2023 |
Eerdere bekende functies van Seth Harmon
| Bedrijven | Functie | Einde |
|---|---|---|
| NEON THERAPEUTICS, INC. | Corporate Officer/Principal | 01-05-2020 |
| BIONTECH SE | Financieel Directeur/CFO | - |
Opleiding van Seth Harmon
| Northeastern University | Graduate Degree |
| Bowdoin College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| BIONTECH SE | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
BioNTech US, Inc.
 BioNTech US, Inc. BiotechnologyHealth Technology BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA. | Health Technology |
